/PRNewswire/ Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC), a healthcare technology company advancing safer use of medications, today announced preliminary,.
Evofem Biosciences Wins Business Intelligence Group s BIG Innovation Award 2021
Evofem honored amongst best companies globally for outstanding innovation with first-in-class non-hormonal prescription contraceptive vaginal gel, Phexxi®
News provided by
Share this article
Share this article
SAN DIEGO, Jan. 12, 2021 /PRNewswire/ Evofem Biosciences, Inc., (NASDAQ: EVFM) has been named a winner of Business Intelligence Group s 2021
BIG Innovation Awards for outstanding innovation with first-in-class non-hormonal prescription contraceptive vaginal gel,
Phexxi® (lactic acid, citric acid and potassium bitartrate). This annual business awards program recognizes organizations, products, and people that are bringing new ideas to life in innovative ways. As a female-led, female-focused company, we put women s needs first and innovate for them. We know firsthand about the serious responsibility and impact of family planning, said Saundra Pelletier, Chief Executive Officer, Evofe
Strategic Healthcare Investment Partners Closes $128M Debut Medical Devices and Digital Health Venture Fund and Rebrands Itself as Treo Ventures
News provided by
Share this article
Share this article
SANTA CLARA, Calif. and DUBLIN, Jan. 12, 2021 /PRNewswire/ Treo Ventures (formerly known as Strategic Healthcare Investment Partners-S.H.I.P.), a venture capital fund focused on investments in high impact companies at the intersection of biology and technology in medical devices and digital health, announced the successful closing of its $128 million debut fund. The fund has a presence in Silicon Valley, CA and Dublin, Ireland, and will be supporting world class entrepreneurs across these geographies. Treo has been actively investing and building a portfolio of category defining companies including Hyalex Orthopedics, CVRx, ShiraTronics, Intuity Medical, NeoChord, and Noctrix Health.
Artios Pharma Expands US Leadership Team with the Appointment of Abid Ansari as Chief Financial Officer
News provided by
Share this article
Share this article
CAMBRIDGE, England and NEW YORK, Jan. 12, 2021 /PRNewswire/ Artios Pharma Limited ( Artios ), a leading DNA Damage Response (DDR) company developing a broad pipeline of precision medicines for the treatment of cancer, announces the appointment of Abid Ansari as Chief Financial Officer (CFO).
Abid will lead the company s financial, investor relations, and public relations operations, where he brings a variety of US financial experience to Artios, including a background with global public companies in corporate finance, business development, licensing, and investor relations. He joins Tania Dimitrova, Chief Business Officer, in the company s US subsidiary established since 2019.
Ariadne Labs Names Two New Members to Advisory Board
News provided by
Share this article
Share this article
BOSTON, Jan. 12, 2021 /PRNewswire/ Today, Ariadne Labs welcomes two new members to its Advisory Board. Elliot Cohen and Karin Leschly will be joining the Advisory Board as trusted advisors and dedicated ambassadors to Ariadne Labs mission to create scalable solutions that improve health care delivery at the most critical moments for people everywhere.
Ariadne Labs welcomes Elliot Cohen and Karin Leschly to its Advisory Board. We are excited to welcome Elliot and Karin to the Advisory Board as we continue to further our goal of improving the delivery of health care in an impactful way that is efficient and equitable. They each bring distinct and exceptional perspectives to this role from prioritizing the underserved to transforming industries that Ariadne Labs will greatly benefit from, said Asaf Bitton, Executive Director, Ariadne Labs.